Swiss National Bank Acquires Shares of 75,100 Theravance Biopharma, Inc. $TBPH

Swiss National Bank acquired a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 75,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,219,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TBPH. Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after acquiring an additional 54,152 shares during the last quarter. State Street Corp lifted its position in Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after acquiring an additional 45,987 shares in the last quarter. Geode Capital Management LLC boosted its stake in Theravance Biopharma by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after purchasing an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Theravance Biopharma by 12.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after purchasing an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the 3rd quarter worth approximately $10,611,000. 99.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TBPH has been the subject of several analyst reports. Weiss Ratings downgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 27th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Finally, B. Riley Financial raised their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Tuesday, April 7th. Eight equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.40.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $16.86 on Friday. Theravance Biopharma, Inc. has a 52-week low of $10.82 and a 52-week high of $21.03. The company has a 50-day simple moving average of $16.71 and a two-hundred day simple moving average of $17.05. The company has a market capitalization of $869.13 million, a price-to-earnings ratio of 7.66 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The firm had revenue of $17.70 million during the quarter. On average, sell-side analysts forecast that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the sale, the insider directly owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is currently owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.